Nuwellis 的 Aquadex 系统超滤疗法可减少 30 天时心力衰竭的再入院率，优于静脉袢利尿剂。 Nuwellis' Aquadex System ultrafiltration therapy reduces heart failure readmissions at 30 days, superior to intravenous loop diuretics.

Nuwellis 宣布 AVOID-HF 试验结果，显示 Aquadex 系统的超滤疗法可减少 30 天时的心力衰竭再入院率，优于静脉袢利尿剂。 Nuwellis announces AVOID-HF trial results, showing Aquadex System's ultrafiltration therapy reduces heart failure readmissions at 30 days, superior to intravenous loop diuretics. 人工智能模型将生活方式和临床因素识别为心力衰竭事件的预测因素。 An AI model identifies lifestyle and clinical factors as predictors of heart failure events. 这些发现支持 Nuwellis 正在进行的 REVERSE-HF 试验，以建立 Aquadex 系统作为心力衰竭的治疗方法。 These findings support Nuwellis' ongoing trial, REVERSE-HF, to establish Aquadex System as a heart failure treatment.